Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Table 1

Studies on VGC in the preemptive setting after alloHSCT.

Author; year [ref.]	Design	N patients	VGC dose	VGC efficacy	Toxicity reported
van der Heiden et al. 2006 [5]	Retrospective; VGC/GCV	34	1800 mg/d	80%	None
Ayala et al. 2006 [6]	Retrospective; VGC mono	18	1800 mg/d ×  14,; → 900 mg/d × ≥7	93%	None
Busca et al. 2007 [7]	Retrospective; VGC mono	15	1800 mg/d × 14,; → 900 mg/d × 14	73%	27% severe hematotoxicity
Candoni et al. 2008 [8]	Retrospective; VGC mono	30	1800 mg/d; versus 900 mg/d	93%; 87%	≤WHO °II
de la Cruz-Vicente et al. 2008 [9]	Prospective; VGC/GCV	11	1800 mg/d × 14,; → 900 mg/d × 14	100%	None
Wang et al. 2008 [10]	Retrospective; VGC mono	19	1800 mg/d × 14,; → 900 mg/d × 14	95%	None
Takenaka et al. 2009 [11]	Retrospective; VGC mono	10	1800 mg/d × 21	90%	10% severe neutropenias
Saleh et al. 2010 [12]	Retrospective; VGC mono	47	1800 mg/d ×≥7,; → 900 mg/d ×≥7	97%	17% severe neutropenias
Palladino et al. 2010 [13]	Retrospective; VGC mono	34	1800 mg/d; versus 900 mg/d	100%; 83%	None
Liu et al. 2010 [14]	Prospective; VGC mono	54	1800 mg/d × 14,; → 900 mg/d × 14	89%	None
Ruiz-Camps et al. 2011 [15]	Prospective; VGC/GCV	166		91%	5% adverse events